Private company

NUNZIA PHARMACEUTICAL Co

NUNZIA PHARMACEUTICAL Co is an American medicinal chemicals and botanical products company.1 It is headquartered in Long Beach, California.1

Last updated Oct 21, 2026.

Overview

  • IndustryMedicinal Chemicals & Botanical Products1
  • HeadquartersLong Beach, California1
  • Incorporated inUT2
  • Business address1627 West 14Th Street, Long Beach, Ca 908132
  • Filer categoryNon-accelerated filer, Smaller reporting company2

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Revenue34$0 in 2021
02019: $0$020192020: $0$020202021: $0$02021
Operating income534-$78.1M in 2021+10408021% since 2015
-$80.0M-$60.0M-$40.0M-$20.0M02015: -$750-$75020152017: -$13.0K-$13.0K2017+1639%2018: -$27.2K-$27.2K2018+108%2019: -$33.6K-$33.6K2019+24%2020: -$39.3K-$39.3K2020+17%2021: -$78.1M-$78.1M2021+198392%
Net income534-$78.1M in 2021+10408269% since 2015
-$150.0M-$100.0M-$50.0M02015: -$750-$75020152017: -$13.0K-$13.0K2017+1639%2018: -$18.6K-$18.6K2018+42%2019: -$33.6K-$33.6K2019+81%2020: -$101.0M-$101.0M2020+300231%2021: -$78.1M-$78.1M2021−23%
Fiscal year2015201620172018201920202021
Revenue$03$04$04
Operating expenses$78.1M4
Operating income-$7505-$13.0K5-$27.2K5-$33.6K3-$39.3K4-$78.1M4
Income tax$03$04$04
Net income-$7505-$13.0K5-$18.6K5-$33.6K3-$101.0M4-$78.1M4
Earnings per share$0.003-$0.354-$0.264
Shares (weighted, basic)305.4M shares4

Compare NUNZIA PHARMACEUTICAL Co with another company

What it owns

What NUNZIA PHARMACEUTICAL Co reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1314 Dec 31, 2021$04 Dec 31, 2020

Leadership

Who has led NUNZIA PHARMACEUTICAL Co, and when. Pick a name to see everywhere that person has worked.

Chief financial officer

  1. Kingman L. Hitz2006
2010201520202025

Former names

  • Arizona Gold & Onyx Mining CoMay 8, 2018 to Jan 3, 20202
  • VIKING CAPITAL GROUP INCNov 20, 1997 to Jul 30, 20102

Timeline

  1. Mar 18, 20228-K Entered a material agreement10
  2. Mar 2, 20228-K Entered a material agreement11

Filings

14 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 2 major events, 3 other. The latest 14:

  1. Jul 20, 202315-12G FORM 15 EDGAR
  2. Nov 14, 202210-Q EDGAR
  3. Oct 3, 202210-Q EDGAR
  4. May 23, 202210-Q QUARTERLY REPORT EDGAR
  5. May 16, 2022NT 10-Q EXTENSION EDGAR
  6. Apr 15, 202210-K EDGAR
  7. Mar 31, 2022NT 10-K EDGAR
  8. Mar 29, 202210-Q/A AMENDMENT #1 TO FORM 10-Q EDGAR
  9. Mar 29, 202210-Q/A AMENDMENT #1 TO FORM 10-Q EDGAR
  10. Mar 29, 202210-Q/A AMENDMENT #1 TO FORM 10-Q EDGAR
  11. Mar 29, 202210-K/A EDGAR
  12. Mar 18, 20228-K NUNZIA PHARMACEUTICAL COMPANY - FORM 8-K SEC FILING EDGAR
  13. Mar 2, 20228-K NUNZIA PHARMACEUTICAL COMPANY - FORM 8-K SEC FILING EDGAR
  14. Nov 10, 202110-Q NUNZIA PHARMACEUTICAL COMPANY - FORM 10-Q SEC FILING EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How NUNZIA PHARMACEUTICAL Co is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNUNZIA PHARMACEUTICAL Co1
  • CIK0000886093
  • Employer ID (EIN)87-04420901
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inUtah1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2833 Medicinal Chemicals & Botanical Products1
  • Business address1627 West 14Th Street, Long Beach, CA 908131
  • Phone714-609-91171
  • Shares outstanding434,514,578 as of Nov 14, 20227
  • Public float$23.0M as of Jun 30, 20214
  • On EDGAR sinceMar 31, 19971
  • Filings208 in all: 4 (46), 8-K (29), 10-Q (27), 10QSB (24), 3 (9), 4/A (9), 10-K (8), 10KSB (8)1
    All 28 form types

    10-Q/A (7), 8-K/A (6), NT 10-K (4), NT 10-Q (4), S-8 (4), 10QSB/A (3), SC 13G/A (3), 10-K/A (2), 15-12G (2), SC 13D/A (2), SC 13G (2), 10-12B (1), 10-12G (1), 10-12G/A (1), 10KSB40 (1), 3/A (1), DEF 14A (1), RW (1), S-8 POS (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Apr 15, 2022
    Quarterly report (10-Q) Nov 14, 2022
    Proxy statement (DEF 14A) Dec 3, 1997
    Latest 8-K (8-K) Mar 18, 2022